Search

Your search keyword '"Zhong, Yahua"' showing total 238 results
Start Over Author "Zhong, Yahua"
238 results on '"Zhong, Yahua"'

5. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study

Author

Xu, Binghe, Sun, Tao, Shi, Yanxia, Cui, Jiuwei, Yin, Yongmei, Ouyang, Quchang, Liu, Qiang, Zhang, Qingyuan, Chen, Yiding, Wang, Shouman, Wang, Xiaojia, Tong, Zhongsheng, Zhong, Yahua, Wang, Jiayu, Yan, Min, Yan, Xi, Wang, Chuan, Feng, Jifeng, Wang, Xiuli, Hu, Gang, Cheng, Ying, Ge, Ruimin, Zhu, Zhaoyin, Zhang, Wa, and Shao, Zhimin

Published
2023
Full Text
View/download PDF

9. Clinical Features and Prognostic Factors of Adenoid Cystic Carcinoma of Head and Neck

Author

WU Fengyang, WU Qiuji, YANG Xiting, and ZHONG Yahua

Subjects
head and neck neoplasms, adenoid cystic carcinoma, prognosis, multivariate regression analysis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Objective To retrospectively analyze the clinical and pathological data of 48 patients with adenoid cystic carcinoma of the head and neck and screen out related factors that affect the patient's prognosis. Methods The overall survival rate of patients is used as the main indicator for observing prognosis. We selected 11 clinical and pathological factors as observation indicators that may have an impact on the survival and prognosis of patients. The relation between observation factors and the overall survival rate of patients was analyzed by Cox multivariate regression. Results The median follow-up time was 33.5(1-98) months. The 1-, 2- and 5-years overall survival rates were 95%, 91% and 87%. Local recurrence occurred in 14(29.2%) patients. Distant metastasis occurred in 22(45.8%) patients. Cox regression analysis showed that recurrence, distant metastasis and primary site were correlated with the overall survival rate of patients with head and neck adenoid cystic carcinoma (P < 0.05). Conclusion Adenoid cystic carcinoma is a relatively rare tumor of the head and neck with a low degree of malignancy. However, recurrence, distant metastasis and primary site have relatively great impact on the prognosis of patients.

Published
2022
Full Text
View/download PDF

10. Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.

Author

Yao, Herui, Yan, Min, Tong, Zhongsheng, Wu, Xinhong, Ryu, Min-Hee, Park, John J., Kim, Jee Hyun, Zhong, Yahua, Zhao, Yiming, Voskoboynik, Mark, Yin, Yongmei, Liu, Kan, Kaubisch, Andreas, Liu, Caigang, Zhang, Jian, Wang, Shouman, Im, Seock-Ah, Ganju, Vinod, Barve, Minal, and Li, Hui

Published
2024
Full Text
View/download PDF

14. Whole-brain radiation therapy plus simultaneous integrated boost for brain metastases from breast cancers.

Author

Zhang, Hongyan, Wu, Qiuji, Li, Li, Wang, Linwei, and Zhong, Yahua

Subjects
INTENSITY modulated radiotherapy, TREATMENT effectiveness, BRAIN metastasis, PROGNOSIS, CANCER prognosis, BREAST
Abstract

Background: The effect of whole-brain radiation therapy (WBRT) plus simultaneous integrated boost (SIB) in brain metastasis from breast cancers has not been demonstrated. Method: In this single-center retrospective study, we reviewed consecutive breast cancer patients who developed brain metastasis and were treated with hypofractionated radiation therapy plus WBRT using intensity-modulated radiation therapy (IMRT)-SIB approaches. We analyzed clinical outcomes, prognostic factors and patterns of treatment failure. Result: A total of 27 patients were eligible for analysis. Four (14.8%) patients achieved clinical complete response and 14 (51.9%) had partial response of brain lesions. The other nine patients were not evaluated for brain tumor response. The median brain progression-free survival was 8.60 (95% CI [6.43–13.33]) months and the median overall survival was 16.8 (95% CI [13.3–27.7]) months. Three patients had in-field failure, five had out-field failure and two had in-field and out-field failure. Conclusion: WBRT plus SIB led to improved tumor control and clinical outcome in breast cancer patients with brain metastasis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Abstract CT175: Safety, tolerability, pharmacokinetics, and antitumor activity of SHR-A1811 in HER2-expressing/mutated advanced solid tumors: A global phase 1, multi-center, first-in-human study

Author

Yao, Herui, primary, Yan, Min, additional, Tong, Zhongsheng, additional, Wu, Xinhong, additional, Ryu, Min-Hee, additional, Kim, Jee Hyun, additional, Park, John, additional, Zhong, Yahua, additional, Han, Weiqing, additional, Liu, Caigang, additional, Voskoboynik, Mark, additional, Qin, Qun, additional, Zhang, Jian, additional, Barve, Minal, additional, Acuna-Villaorduna, Ana, additional, Ganju, Vinod, additional, Im, Seock-Ah, additional, Ye, Changsheng, additional, Yin, Yongmei, additional, Roy, Amitesh C., additional, Bai, Li-Yuan, additional, Lin, Yung-Chang, additional, Yen, Chia-Jui, additional, Li, Hui, additional, Chung, Ki Young, additional, Gu, Shanzhi, additional, Qian, Jun, additional, Teng, Yuee, additional, Chen, Yiding, additional, Shen, Yu, additional, Zhao, Kaijing, additional, Rong, Shangyi, additional, Zhu, Xiaoyu, additional, and Song, Erwei, additional

Published
2023
Full Text
View/download PDF

26. Effects of induction chemotherapy on nutrition status in locally advanced nasopharyngeal carcinoma: a multicentre prospective study

Author

Miao, Jingjing, primary, Wang, Lin, additional, Ong, Enya H.W., additional, Hu, Chaosu, additional, Lin, Shaojun, additional, Chen, Xiaozhong, additional, Chen, Yuanyuan, additional, Zhong, Yahua, additional, Jin, Feng, additional, Lin, Qin, additional, Lin, Shaomin, additional, Hu, Xuefeng, additional, Zhang, Ning, additional, Wang, Rensheng, additional, Wang, Cong, additional, Guo, Xiang, additional, Yit, Nelson L.F., additional, Shi, Hanping, additional, Tan, Sze Huey, additional, Mai, Haiqiang, additional, Xie, Conghua, additional, Chua, Melvin L.K., additional, and Zhao, Chong, additional

Published
2023
Full Text
View/download PDF

28. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study

Author

Xu, Binghe, primary, Sun, Tao, additional, Shi, Yanxia, additional, Cui, Jiuwei, additional, Yin, Yongmei, additional, Ouyang, Quchang, additional, Liu, Qiang, additional, Zhang, Qingyuan, additional, Chen, Yiding, additional, Wang, Shouman, additional, Wang, Xiaojia, additional, Tong, Zhongsheng, additional, Zhong, Yahua, additional, Wang, Jiayu, additional, Yan, Min, additional, Yan, Xi, additional, Wang, Chuan, additional, Feng, Jifeng, additional, Wang, Xiuli, additional, Hu, Gang, additional, Cheng, Ying, additional, Ge, Ruimin, additional, Zhu, Zhaoyin, additional, Zhang, Wa, additional, and Shao, Zhimin, additional

Published
2022
Full Text
View/download PDF

34. Identification of Two m6A Readers YTHDF1 and IGF2BP2 as Immune Biomarkers in Head and Neck Squamous Cell Carcinoma

Author

Li, Shaojie, Wu, Qiuji, Liu, Jia, and Zhong, Yahua

Subjects
Genetics, Molecular Medicine, Genetics (clinical)
Abstract

Background: N6-methyladenosine (m6A) is the most abundant internal modification pattern in mammals that a plays critical role in tumorigenesis and immune regulations. However, the effect of m6A modification on head and neck squamous cell carcinoma (HNSCC) has not been clearly studied.Methods: We screened m6A regulators that were significantly correlated with tumor immune status indicated by ImmuneScore using The Cancer Genome Atlas (TCGA) dataset and obtained distinct patient clusters based on the expression of these m6A regulators with the R package “CensusClusterPlus.” We then performed gene set enrichment analysis (GSEA), CIBERSORT, and single-sample gene set enrichment analysis (ssGSEA) to assess the differences in gene function enrichment and tumor immune microenvironment (TIME) among these clusters. We further conducted differently expressed gene (DEG) analysis and weighted gene co-expression network analysis (WGCNA) and constructed a protein–protein interaction (PPI) network to determine hub genes among these clusters. Finally, we used the GSE65858 dataset as an external validation cohort to confirm the immune profiles related to the expression of m6A regulators.Results: Two m6A readers, YTHDF1 and IGF2BP2, were found to be significantly associated with distinct immune status in HNSCC. Accordingly, patients were divided into two clusters with Cluster 1 showing high expression of YTHDF1 and IGF2BP2 and Cluster 2 showing low expression levels of both genes. Clinicopathologically, patients from Cluster 1 had more advanced T stage and pathological grades than those from Cluster 2. GSEA showed that Cluster 1 was closely related to the RNA modification process and Cluster 2 was significantly correlated with immune regulations. Cluster 2 had a more active TIME characterized by a more relative abundance of CD8+ T cells and CD4+ T cells and higher levels of MHC I and MHC II molecules. We constructed a PPI network composed of 16 hub genes between the two clusters, which participated in the T-cell receptor signaling pathway. These results were externally validated in the GSE65858 dataset.Conclusions: The m6A readers, YTHDF1 and IGF2BP2, were potential immune biomarkers in HNSCC and could be potential treatment targets for cancer immunotherapy.

Published
2022
Full Text
View/download PDF

35. Phase I/IIa study of PM8001, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced tumors.

Author

Guo, Ye, primary, Liu, Baogang, additional, Lv, Dongqing, additional, Cheng, Ying, additional, Zhou, Tong, additional, Zhong, Yahua, additional, Hu, Changlu, additional, Chen, Gang, additional, Wu, Xiaohua, additional, Yin, Yongmei, additional, Wu, Lihua, additional, Chen, Zhendong, additional, Luo, Hong, additional, Zhou, Xiaohong, additional, Qin, Yanru, additional, Yang, Yuxing, additional, Luo, SuXia, additional, Ma, Yanjie, additional, Li, Yalin, additional, and Hu, Guoqiang, additional

Published
2022
Full Text
View/download PDF

38. Ataxia telangiectasia mutated kinase inhibition promotes irradiation‐induced PD‐L1 expression in tumour‐associated macrophages through IFN‐I/JAK signalling pathway.

Author

Gao, Yuke, Li, Yangyi, Lin, Zaihuan, Zeng, Yuxin, Huang, Zhengrong, Han, Linzhi, Zhong, Yahua, Gong, Yan, Wu, Qiuji, and Xie, Conghua

Subjects
ATAXIA telangiectasia, PROGRAMMED death-ligand 1, CELLULAR signal transduction, INTERFERON regulatory factors, TYPE I interferons
Abstract

Tumour‐associated macrophages (TAMs) are one of the primary sources of PD‐L1 expression in the tumour microenvironment (TME). Ionizing radiation (IR) promotes PD‐L1 expression in tumour cells. However, the effect of IR on macrophage PD‐L1 expression and the underlying mechanisms remain unclear. ATM kinase, as the key kinase for initiating DNA damage repair (DDR) process, is associated with innate immune STING axis activation. Here, we explored the molecular mechanism implicated in macrophage PD‐L1 expression regulated by IR as well as the role of ATM kinase in this process. IR‐regulated PD‐L1 expression in macrophages and associated signalling pathways were explored by in vitro studies using murine and human macrophage cell lines. A colorectal xenograft murine model was employed to demonstrate the impact of targeting ATM and PD‐L1 expression in TAMs following IR on growth of tumour in vivo. IR up‐regulated PD‐L1 expression in macrophages, which was further augmented by ATM kinase inhibition. ATM inhibition increased IR‐induced DNA damage, which activated STING/interferon regulatory factor 3 (IRF3) signalling pathway and up‐regulated type I interferon (IFN‐I) expression in macrophages. IFN‐I bound to the IFN α receptor 1 on macrophages, activated the downstream JAK1 and STAT1/3 signalling and eventually led to PD‐L1 up‐expression. ATM inhibition augmented IR‐induced PD‐L1 expression in macrophages and CD8+ T cell infiltration, and promoted anti‐tumour efficacy in vivo. These results suggested that ATM inhibition promoted IR‐induced PD‐L1 expression through the activation of innate immunity in TAMs, which provided a novel approach to enhance the anti‐tumour efficacy of RT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. HPV Positive Status Is a Favorable Prognostic Factor in Non-Nasopharyngeal Head and Neck Squamous Cell Carcinoma Patients: A Retrospective Study From the Surveillance, Epidemiology, and End Results Database

Author

Wu, Qiuji, primary, Wang, Miao, additional, Liu, Yixin, additional, Wang, Xulong, additional, Li, Yi, additional, Hu, Xiaoyan, additional, Qiu, Ye, additional, Liang, Wenjing, additional, Wei, Yongchang, additional, and Zhong, Yahua, additional

Published
2021
Full Text
View/download PDF

47. A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.

Author

Sun, Tao, primary, Shi, Yanxia, additional, Cui, Jiuwei, additional, Yin, Yongmei, additional, Ouyang, Quchang, additional, Liu, Qiang, additional, Zhang, Qingyuan, additional, Chen, Yiding, additional, Zhimin, Shao, additional, Wang, Shouman, additional, Wang, Xiaojia, additional, Tong, Zhongsheng, additional, Zhong, Yahua, additional, Yan, Min, additional, Yan, Xi, additional, Wang, Chuan, additional, Yang, Haiyuan, additional, Li, Miao, additional, Xiang, Xiao, additional, and Xu, Binghe, additional

Published
2021
Full Text
View/download PDF

48. Outcomes in Radiotherapy-Treated Patients With Cancer During the COVID-19 Outbreak in Wuhan, China

Author

Conghua Xie, Hui Liu, Melvin L.K. Chua, Zhong Yahua, Zhirong Bao, Xiaoyong Wang, and Jing Yu

Subjects
Male, Cancer Research, Pediatrics, medicine.medical_specialty, 2019-20 coronavirus outbreak, China, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medicine.medical_treatment, Treatment outcome, Pneumonia, Viral, Disease Outbreaks, 03 medical and health sciences, Betacoronavirus, 0302 clinical medicine, Neoplasms, medicine, Research Letter, Humans, Online First, 030212 general & internal medicine, Letters, Pandemics, business.industry, SARS-CoV-2, Research, Outbreak, Cancer, COVID-19, General Medicine, Middle Aged, medicine.disease, Radiation therapy, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, business, Coronavirus Infections, Comments
Abstract

This case series evaluated the delivery of radiotherapy in 209 patients with cancer during the COVID-19 outbreak in Wuhan, China.

Published
2020

49. Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors

Author

Hongyan Zhang, Xianglin Yuan, Zhong Yahua, Qiuji Wu, Xudong He, Qian Chu, Conghua Xie, Melvin L.K. Chua, and Bin Yang

Subjects
Cancer Research, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Immune checkpoint inhibitors, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pneumonia, Viral, lcsh:RC254-282, Betacoronavirus, Neoplasms, Pandemic, Medicine, Humans, Viral immunology, Letter to the Editor, Pandemics, business.industry, SARS-CoV-2, Cancer, COVID-19, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Virology, Pneumonia, Treatment Outcome, Oncology, Immunotherapy, business, Coronavirus Infections
Published
2020

50. Outcomes of novel coronavirus disease 2019 (COVID‐19) infection in 107 patients with cancer from Wuhan, China

Author

Gaili Chen, Yuan-Yuan Chen, Hongyan Zhang, Linwei Wang, Qiuji Wu, Xinghuan Wang, Xiao-Kun Shen, Yi Yu, Zhong Yahua, Conghua Xie, Qun Wang, You-Qin Yan, and Melvin L.K. Chua

Subjects
Male, Cancer Research, anticancer treatment, Medical Oncology, Severity of Illness Index, systemic therapy, 0302 clinical medicine, Neoplasms, Case fatality rate, 030212 general & internal medicine, Aged, 80 and over, case fatality rate, Incidence, Incidence (epidemiology), Hazard ratio, Immunoglobulins, Intravenous, Middle Aged, Survival Rate, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, Steroids, Original Article, Coronavirus Infections, Adult, Risk, China, medicine.medical_specialty, Pneumonia, Viral, Antineoplastic Agents, Antiviral Agents, Discipline, Betacoronavirus, 03 medical and health sciences, Internal medicine, Correspondence, Severity of illness, medicine, Humans, cancer, Pandemics, Survival rate, Aged, Retrospective Studies, SARS-CoV-2, business.industry, Genitourinary system, COVID-19, Cancer, Retrospective cohort study, Original Articles, medicine.disease, coronavirus disease 2019 (COVID‐19), business
Abstract

Background Patients with cancer have a higher risk of coronavirus disease 2019 (COVID‐19) than noncancer patients. The authors conducted a multicenter retrospective study to investigate the clinical manifestations and outcomes of patients with cancer who are diagnosed with COVID‐19. Methods The authors reviewed the medical records of hospitalized patients who were treated at 5 hospitals in Wuhan City, China, between January 5 and March 18, 2020. Clinical parameters relating to cancer history (type and treatment) and COVID‐19 were collected. The primary outcome was overall survival (OS). Secondary analyses were the association between clinical factors and severe COVID‐19 and OS. Results A total of 107 patients with cancer were diagnosed with COVID‐19, with a median age of 66 years (range, 37‐98 years). Lung (21 patients; 19.6%), gastrointestinal (20 patients; 18.7%), and genitourinary (20 patients; 18.7%) cancers were the most common cancer diagnoses. A total of 37 patients (34.6%) were receiving active anticancer treatment when diagnosed with COVID‐19, whereas 70 patients (65.4%) were on follow‐up. Overall, 52.3% of patients (56 patients) developed severe COVID‐19; this rate was found to be higher among patients receiving anticancer treatment than those on follow‐up (64.9% vs 45.7%), which corresponded to an inferior OS in the former subgroup of patients (hazard ratio, 3.365; 95% CI, 1.455‐7.782 [P = .005]). The detrimental effect of anticancer treatment on OS was found to be independent of exposure to systemic therapy (case fatality rate of 33.3% [systemic therapy] vs 43.8% [nonsystemic therapy]). Conclusions The results of the current study demonstrated that >50.0% of infected patients with cancer are susceptible to severe COVID‐19. This risk is aggravated by simultaneous anticancer treatment and portends for a worse survival, despite treatment for COVID‐19., Patients with cancer who are receiving anticancer treatment have a 3‐fold higher risk of death from coronavirus disease 2019 (COVID‐19) than those on follow‐up. The authors report that this detrimental effect on survival appears to be independent of anticancer treatment modalities.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results